Dengue virus (DV) infection causes a spectrum of disease ranging from self-limited Dengue Fever to lifethreatening Dengue Hemorrhagic Fever/Dengue Shock Syndrome. The mechanisms of immune protection and pathogenesis are poorly understood, but DV nonstructural protein 1 (NS1) likely plays a key role. NS1 is present in the cytoplasm and on the surface of infected cells and is secreted in a soluble form (sNS1) that circulates in blood, where high sNS1 concentration correlates with increased disease severity. In vitro, sNS1 can activate complement, bind to infected and uninfected cells, and increase viral output from infected hepatoma cells. However, it is unclear if or how sNS1 affects viral dissemination or disease progression in vivo. Similarly, the role of antibodies (Abs) against NS1 is unclear due to the lack of appropriate in vivo models. Anti-NS1 Abs display protective activity against neurovirulent death in mice, but the effects of anti-NS1 Abs on DV infection of more relevant peripheral tissues have never been characterized. Nonetheless, NS1 is included in several DV vaccines under development, including that of our collaborator, Hawaii Biotech, Inc., and no test exists to evaluate the repertoire of Abs generated by either natural infection or vaccination. We have shown that DV infection of interferon receptor-deficient mice reproduces key features of human DV infection, including susceptibility to all four DV serotypes with relevant infection kinetics, appropriate tissue and cellular tropism, sNS1 circulation in the blood, thrombocytopenia correlated with viral load, and fatal vascular leak syndrome. We will use this mouse model to examine the functions of sNS1 and the effects of anti-NS1 Abs on DV infection. We will also use sera obtained from mice, prospective studies of dengue in Nicaragua, and dengue vaccine trials to generate in vitro assays to assess the repertoire of anti-NS1 Abs in infected mice, primary and secondary natural DV infections, and vaccine recipients.
In Specific Aim 1, we will assess the localization and function of sNS1 during DV infection in mice and fatal human dengue cases.
In Specific Aim 2, the effects of anti-NS1 Abs on peripheral DV infection in mice will be evaluated. We will measure the ability of both polyclonal Abs and MAbs against NS1 to protect against DV infection using both NS1 vaccination and MAbs against DV2 NS1, and we will screen for any detrimental in vivo effects of NS1 Abs. Finally, in Specific Aim 3, we will characterize the repertoire of anti-NS1 Abs generated by DV infection and vaccination and will develop in vitro tests to detect anti-NS1 Abs in human serum likely to have protective or pathogenic effects during subsequent DV infection. Together, these results will both elucidate mechanisms of DV pathogenesis and contribute to the development of a safe and effective dengue vaccine.

Public Health Relevance

Although dengue virus (DV) nonstructual protein 1 (NS1) is produced by most vaccines in clinical trials, it is not clear if anti-NS1 Abs contribute to protection or pathogenesis. Also, the function of NS1 in vivo is not well defined. We propose to characterize the cellular targets and functions of sNS1 in vivo, the effect of anti-NS1 Abs on DV infection and pathogenesis, and the repertoire of anti-NS1 Abs elicited by natural DV infection and vaccination in mice and humans. In addition, our mouse model allows questions regarding dengue immunity and pathogenesis, as well as evaluation of candidate therapeutics and vaccines, to be addressed.

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Specialized Center--Cooperative Agreements (U54)
Project #
Application #
Study Section
Special Emphasis Panel (ZAI1-DDS-M)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of California Irvine
United States
Zip Code
Waggoner, Jesse J; Gresh, Lionel; Mohamed-Hadley, Alisha et al. (2016) Single-Reaction Multiplex Reverse Transcription PCR for Detection of Zika, Chikungunya, and Dengue Viruses. Emerg Infect Dis 22:1295-7
Ziegler, Christopher M; Eisenhauer, Philip; Bruce, Emily A et al. (2016) The Lymphocytic Choriomeningitis Virus Matrix Protein PPXY Late Domain Drives the Production of Defective Interfering Particles. PLoS Pathog 12:e1005501
Barbour, Alan G (2016) Infection resistance and tolerance in Peromyscus spp., natural reservoirs of microbes that are virulent for humans. Semin Cell Dev Biol :
Park, Arnold; Yun, Tatyana; Hill, Terence E et al. (2016) Optimized P2A for reporter gene insertion into Nipah virus results in efficient ribosomal skipping and wild-type lethality. J Gen Virol 97:839-43
Levin, Mattias; King, Jasmine J; Glanville, Jacob et al. (2016) Persistence and evolution of allergen-specific IgE repertoires during subcutaneous specific immunotherapy. J Allergy Clin Immunol 137:1535-44
Chomel, Bruno B; Molia, Sophie; Kasten, Rickie W et al. (2016) Isolation of Bartonella henselae and Two New Bartonella Subspecies, Bartonellakoehlerae Subspecies boulouisii subsp. nov. and Bartonella koehlerae Subspecies bothieri subsp. nov. from Free-Ranging Californian Mountain Lions and Bobcats. PLoS One 11:e0148299
Kern, Aurelie; Zhou, Chensheng W; Jia, Feng et al. (2016) Live-vaccinia virus encapsulation in pH-sensitive polymer increases safety of a reservoir-targeted Lyme disease vaccine by targeting gastrointestinal release. Vaccine 34:4507-13
Zeltina, Antra; Bowden, Thomas A; Lee, Benhur (2016) Emerging Paramyxoviruses: Receptor Tropism and Zoonotic Potential. PLoS Pathog 12:e1005390
Waggoner, Jesse J; Ballesteros, Gabriela; Gresh, Lionel et al. (2016) Clinical evaluation of a single-reaction real-time RT-PCR for pan-dengue and chikungunya virus detection. J Clin Virol 78:57-61
Sanman, Laura E; Qian, Yu; Eisele, Nicholas A et al. (2016) Disruption of glycolytic flux is a signal for inflammasome signaling and pyroptotic cell death. Elife 5:e13663

Showing the most recent 10 out of 434 publications